BMS's Sprycel gets FDA priority review for newly diagnosed CML
This article was originally published in Scrip
Executive Summary
The supplemental NDA for Bristol-Myers Squibb/Otsuka Pharmaceutical's second generation BCR-ABL inhibitor Sprycel (dasatinib) for the treatment of newly diagnosed, chronic-phase chronic myeloid leukaemia (CML) has been accepted for filing by the US FDA and been granted a priority review designation.